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Genetic Analysis of Families with Parkinson Disease
that Carry the Ala53Thr Mutation in the Gene
Encoding a-Synuclein
To the Editor:
Linkage of Parkinson disease (PD; MIM 601508) to a
highly penetrant genetic locus on chromosome4q21-q23
(Polymeropoulos et al. 1996) was soon followed by the
detection of a missense mutation, in the a-synuclein gene
(SNCA; MIM 163890) segregating with the disease
(Chen et al. 1995; Polymeropoulos et al. 1997). The
mutation was a 209GrA substitution in exon 4 of the
gene, resulting in an Ala53Thr mutation in the a-syn-
uclein protein and this change was predicted to revert
the whole structure of the protein into beta-pleated
sheets, which, in turn, may be involved in the self-ag-
gregation of proteins. This mutation was first identified
in a large Italian kindred and three unrelated Greek fam-
ilies, and later it was reported in twomoreGreek families
(Papadimitriou et al. 1999). However, it was absent from
several hundred cases of familial PD investigated by
groups in the United States (Chan et al. 1998a, 1998b;
Farrer et al. 1998) as well as in Europe (Munoz et al.
1997; Bennett and Nicholl 1998; Vaughan et al. 1998;
Zareparsi et al. 1998), indicating that it is indeed a rare
cause of PD. A 88GrC nucleotide substitution in exon
3, resulting in an Ala30Pro mutation was subsequently
detected in a German patient with autosomal dominant
PD (Kruger et al. 1998), giving further support to the
hypothesis that a-synuclein could participate in the path-
ogenesis of the disease. That impaired degradation of
abnormal proteins could play a role in PD—and, pos-
sibly, in other degenerative disorders—was also sug-
gested by the detection of a mutation in the ubiquitin
C-terminal hydrolase-L1 (UCH-L1) in a German family
(Leroy et al. 1998).
a-Synuclein is a presynaptic-nerve terminal protein,
identified as a precursor protein for the non-b amyloid
component of amyloid plaques in Alzheimer Disease
(AD) (Ueda et al. 1993; Ueda et al. 1994; Campion et
al. 1995; Jensen et al. 1995). The wild type a-synuclein
protein is present in the Lewy bodies of familial and
sporadic PD patients (Spillantini et al. 1997; Baba et al.
1998).
We present here a molecular-genetic analysis of PD
families, with respect to mutations in the a-synuclein
gene. Our study was approved by the Ethics Committee
of the Medical School of the University of Patras and
involved patients with familial PD and as many of their
relatives as possible, as well as sporadic PD patients, all
voluntary donors of a blood sample. Donors were in-
formed of the content and purpose of the research pro-
ject and signed an informed-consent form. Ten ml of
blood were collected, in presence of EDTA, from each
donor.When possible, a second blood sample was drawn
from a patient in each family and was used for lym-
phocyte transformation to provide permanent access to
their DNA.
We studied a total of 19 unrelated families, in each
of which there were at least two first- or second-degree
relatives affected with PD. The three Greek families re-
ported on elsewhere (Polymeropoulos et al. 1997) were
included in the study and are analyzed here in an ex-
panded form. Our study involves the recording of ped-
igrees of at least three successive generations, the re-
cording of available clinical data, and the molecular
analysis of the DNA extracted from the blood of patients
and their unaffected relatives. Seven of these families had
multiple affected members and showed a pattern con-
sistent with autosomal dominant inheritance. The pen-
etrance appeared high, since among family members of
age 147 years who were offspring of an affected indi-
vidual, approximately half were affected (6/13–3/5). All
affected individuals had one affected parent, and both
males and females transmitted the trait (Mange and
Mange 1994). The first clinical data available for the
patients of these seven families are given in table 1.
DNA was extracted from peripheral blood and was
used for PCR amplification of a-synuclein exon 4, by
use of primers 3 and 13 (Polymeropoulos et al. 1997).
Exon 3 was amplified by use of forward primer
ACTTTGGAGGGTTTCTCATG and reverse primer
TGTTATCCTAACCCATCAC. PCRs were prepared in
a volume of 100 ml, and 2.5 units of DNA polymerase
(GIBCO-BRL) were used. The Tsp45I and MvaI diges-
tions of PCR products containing exons 4 and 3, re-
spectively, were performed according to the supplier’s
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Table 1
Clinical and Molecular Analysis of Patients Carrying the Ala53 Thr Mutation
FAMILY PATIENT SEX
AGE
(YEARS)
AGE AT ONSET
(YEARS)
STATUSa
Bradykinesia
Muscular
Rigidity
Resting
Tremor
Ala53Thr
Mutation
PDGR1 II3 M 58 52        
PDGR2 III1 F 54 50        
PDGR5 III1 F 80 76        
PDGR5 III2 M 68 58        
PDGR5 IV5 F 40 36        
PDGR8 IV1 M 48 43        
PDGR8 IV6 M 48 47        
PDGR11 III1 F 57 49       
PDGR11 III9 F 57 51       
PDGR15 III15 M 49 40       
PDGR18 III4 M 61 58        
  Symptom weakly present;   present;   strongly present;   absent.
Table 2
Markers Used for Haplotyping, and the Primers that Generated the Respective Alleles
MARKER REPEAT
PCR PRIMER (5′r3′)
PIC ALLELE
SIZE
(bp)
ALLELE
FREQUENCYaForward Reverse
TA46 (TA)25 TGTTTGCTACGACATCTCTC CTTGAGCCAGAAGGTTGAGG .76 1 107 .07
2 109 .3
3 111 .28
4 113 .07
5 115 .13
6 117 .11
7 119 .04
SYN24,25 (TA)7(CA)11 AGGATGGATTAGTAGCTATG CCTATGGAAGACATGAAGAC .40 1 181 .27
2 183 .67
3 185 .04
4 187 .01
aFrequencies based on 56 chromosomes for TA46 and on 92 chromosomes for SYN24,25
directions. The digested material was electrophoresed in
4% Nusieve agarose gel.
Ten microsatellite markers (Gyapay et al. 1994) were
used in the haplotype analysis, including two new poly-
morphisms. The order of the eight previously described
genetic markers, from centromere to telomere, is
D4S2361-D4S2460-D4S2371-D4S2461-D4S3006-
D4S1089-D4S414-D4S2380. The genetic markers were
ordered by use of a minimal physical YAC contig. The
two additional genetic markers used were (1) TA46, a
(TA)n repeat that was generated from the bacterial ar-
tificial chromosome clone 225H6 (Research Genetics)
and that contains marker D4S2461 and (2) marker SYN
24,25, which was designed to flank a dinucleotide repeat
in the 5′ noncoding region of the a-synuclein gene
(GenBank U46895) (table 2).
The Ala53Thr a-synuclein mutation (Polymeropoulos
et al. 1997) was detected in 10 patients belonging to the
seven autosomal dominant families but was not found
in any member of the remaining 12 families (table 1).
In patients carrying the mutation the mean age at onset
of the disease is 4711 years, which is considered to
be “early onset” PD. Interestingly, one patient from fam-
ily PDGR5, individual III-1, did not carry the Ala53Thr
mutation, although the mutation was detected in two
other affected members of that family. This patient had
a much later age at onset of the disease, 76 years, and
may represent “sporadic” PD. None of 41 sporadic PD
patients of local origin, in 13 of whom the age at onset
was 35–55 years, carried the mutation. The DNAs from
116 nonaffected members of the seven families were also
analyzed. Among them, we found 11 unaffected carriers
of the Ala53Thr mutation (not shown), 10 of whom
were younger than the mean age at onset. All of these
11 patients had one affected parent carrying the muta-
tion. However, these results are consistent with a high
penetrance of the Ala53Thr mutation in the families that
we studied, with age at onset 160 years, as was the case
in the Contursi family, the original family studied (Po-
lymeropoulos et al. 1997). Finally, we analyzed 100
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Figure 1 Chromosome 4 haplotype analysis of families carrying
the Ala53Thr mutation. The unblackened and blackened symbols rep-
resent unaffected and affected individuals, respectively. Roman nu-
merals indicate generations, and arabic numerals indicate individuals.
The shared haplotype is boxed.
chromosomes from 50 healthy control individuals, de-
riving mainly from the Peloponnese and from western
Greece, and found none carrying the mutation. Neither
any of the patients with familial PD nor any of those
with sporadic PD carried the Ala30Pro mutation.
In the Contursi kindred, polymorphic markers estab-
lished a haplotype shared by all the affected individuals
of the kindred, within a region of ∼6 cM harboring the
a-synuclein gene. To assess the possibility that a founder
chromosome is shared by the southern Italian kindred
and the seven Greek families that carry the Ala53Thr
mutation, we used 10 polymorphic markers to genotype
members of three Greek families carrying the mutation
(fig. 1). The Greek patients with PD share the portion
of chromosome 4 shared by the Contursi kindred, de-
lineated by marker D4S2460 at the centromeric end and
by marker D4S3006 at the telomeric end.
On the basis of the information currently available, it
appears that these patients with the Ala53Thr a-synu-
clein mutation have an average age at onset that is at
or below the average age at onset in sporadic PD. Clin-
ically, they have prominent bradykinesia and muscular
rigidity but rarely have tremor. A more detailed study is
currently underway to determine the specific clinical phe-
notype that may be associated with the a-synuclein
Ala53Thr mutation.
All seven Greek families with PD originate from three
villages of the northern Peloponnese in Greece, two of
which are only 17 km apart and are villages of origin
for six of the families. The village of origin of the seventh
family was 120 km distant . The Contursi kindred comes
from southern Italy, a region geographically and histor-
ically linked to Greece. Our data suggest that affected
members in these families may all be descendents of a
single founder. A study of “early-onset” familial PD in
the greater Balkan area would help to establish the con-
tribution of a-synuclein mutations to the PD phenotype.
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Mutation of the XNP/ATR-X Gene in a Family with
Severe Mental Retardation, Spastic Paraplegia and
Skewed Pattern of X Inactivation: Demonstration that
the Mutation is Involved in the Inactivation Bias
To the Editor:
A family in which severe mental retardation (MR) is
segregating with spastic paraplegia (SP) has recently
been reported (Martinez et al. 1998). The extended ped-
igree of this family is presented in figure 1. Obligate-
carrier females have a totally skewed pattern of X in-
activation, detected by amplification of the (CAG)n mi-
crosatellite repeat in the androgen-receptor gene and pre-
vious digestion of genomic DNA with the methy-
lation-sensitive restriction endonuclease HpaII, as de-
scribed elsewhere (Martinez et al. 1998). Genetic anal-
ysis in the family has revealed linkage of the morbid
locus to the proximal long arm of the X chromosome,
with a maximum LOD score in Xq13.3. Three genes
involved in X-linked MR (XLMR) have already been
reported in this genomic region. One, encoding oligo-
phrenin-1, is involved in nonsyndromic XLMR (Billuart
et al. 1998) and thus does not seem to be a good can-
didate. The other two are involved in two syndromic
XLMR conditions: Menkes syndrome (MIM 309400)
and alpha-thalassemia with mental retardation (ATR-X
[MIM 301040]) syndrome. The latter is an XLMR con-
dition that associates severe MR, mild alpha-thalasse-
mia, typical facial dysmorphy and a skewed pattern of
X inactivation in carrier females (Gibbons et al. 1995a).
The clinical characteristics of the reported MRSP fam-
ily are close to this description, and thus the presence
of an allelic mutation at the ATR-X locus could be hy-
pothesized. In addition to the already reported clinical
features in the MRSP family, hematologic analysis re-
vealed that 3% of the patients’ erythrocytes showed
HbH inclusions after cresyl-brilliant staining, which re-
inforced the possibility that a mutation in the XNP/ATR-
X gene is present in this family. However, ATR-X syn-
drome has always been reported to be associated with
neonatal hypotonia, which can be severe (Gibbons et al.
1995a). In the case of the family that we studied, affected
